Anemia Clinical Trial
Official title:
Improving Iron Status of Children in a Semi-arid Area of Kenya: the Potential of Amaranth Grain Flour
Introduction: Iron deficiency anaemia remains a significant public health challenge.
Localized food based approaches may offer a large opportunity to improve lives and address
the widespread micronutrient deficiencies such as iron in affected households. Viable
solutions where iron rich foods are not readily available may come through diversification
approaches using foods such as amaranth grain reported to contain high iron content and good
quality protein in conjunction with the use of in-home fortification.
Objectives: To determine the efficacy of maize porridge enriched with amaranth flour on
improving diet quality, iron intake and status in children 12-59 months in a semiarid area
in Kenya.
Study population: The study population will comprise children aged 12-59 months in Migwani,
within the larger Mwingi district, Kenya. Mothers or principal caretakers will be
interviewed on behalf of the children. In total, 270 children will be enrolled in the study.
Study design:
The study has a randomized controlled trial design conducted over a period of 4 months/16
weeks.
Treatment/hypothesis: All participating children will be required to take the provided
porridge equivalent to 80g of flour 5 days a week for 16 weeks. There will be 3 treatments
groups as follows; (1) maize porridge enriched with amaranth grain flour at 70:30
maize/amaranth ratio, (2) maize porridge fortified with a multiple micronutrient powder
(MixMe™) and (3) plain maize porridge group. Hypothesis: there will be a significant
difference in hemoglobin and iron status between the three groups.
Methods: Blood samples (5ml) will be collected by veni-puncture at baseline and after
intervention. Hb concentration, Zinc protoporphyrin (ZnPP) and malaria infection will be
assessed in the field. Analyses of serum ferritin, serum transferrin receptor and C-reactive
protein (CRP) will be done at the participating laboratories.
Main study parameter/Endpoints: Change in Hb concentration is the primary outcome of this
study. Body iron measured by serum ferritin (SF) and serum transferrin receptor (STfR) are
the secondary outcome. Iron deficiency will be defined as SF concentration <12 µg/L and
tissue iron deficiency will be defined as serum transferrin receptor concentration of
>8.3mg/L. Infection will be assessed by raised CRP (>10mg/L) as an indicator of acute
inflammation and presence of malaria.
Background and Rationale The most severe problems of micronutrient deficiency are found
amongst resource poor, food insecure and vulnerable households in developing countries. From
the 1999 Kenya national survey on micronutrients, it was estimated that seven out of every
ten children under five years are likely to be anaemic (Hb<110g/L) and nearly half (43.2%)
were iron deficient.
The period of complementary feeding is a critical and vulnerable time in the growth and
development of children. Poor complementary feeding practices combined with chronic food
insecurity are found to substantially contribute to the widespread multiple micronutrients
deficiencies in developing countries.
A recent food consumption study in Mwingi district in Kenya, showed that ugali (stiff maize
porridge) was the primary complementary food. The use of ugali as the primary complementary
food suggests that the children may be at risk of inadequate micronutrient intake among
children 12-23 months. These findings underscore the need to establish solutions to increase
dietary diversity and to promote use of foods that are rich in nutrients such as iron.
Amaranth grain offers the prospect of considerably improving dietary food diversification in
semi arid areas. Agronomic investigations indicate that amaranth grain contains high iron
concentrations ranging from 7.6-27 mg/100g of edible portion. Amaranth grain is a hardy crop
and can withstand low rainfall. As such, grain amaranth may offer a viable solution in
semi-arid areas where iron rich foods such as animal and fortified products are not readily
available.
This study has therefore been designed to investigate the efficacy of porridge made from
amaranth enriched maize flour in improving the diet quality and iron intake in children
12-59 months in a semi-arid area in Kenya. Home fortification of complementary foods using
micronutrient powders has also been shown to reduce iron deficiency anaemia in many
resource-poor settings including Kenya.
Objectives The primary objective of this study is To determine the efficacy of maize
porridge enriched with amaranth grain flour on improving iron intake and status in children
12-59 months in a semi arid area in Kenya.
In addition we aim:
- To determine the efficacy of amaranth grain enriched maize porridge compared to maize
porridge fortified with micronutrient multi-mix powder (MixMe™) to improve iron status
and intake of children 12-59 months.
- To determine the iron, zinc and nutritional status of children 12-59 months.
Hypothesis
We hypothesize that:
- Children receiving amaranth grain enriched maize porridge will show greater improvement
in iron status than those receiving plain maize porridge.
- Children receiving amaranth enriched maize porridge will show less improvement in iron
status than those receiving maize porridge fortified with micronutrient multi-mix
powder (MixMe™).
Study Area and Population The study will be conducted in Migwani within the larger Mwingi
District in Eastern Kenya. This area falls within the arid and semi arid area (ASAL) and
thus experiences food shortage for most part of the year. The study population will comprise
children aged 12-59 months. Mothers or principal caretakers will be interviewed on behalf of
the children.
Study Design The study will have a randomized controlled trial design conducted over a
period of 4 months/16 weeks.
The administrative study area has been purposively selected as it falls within an
agro-ecological zone of a semi-arid area. Random sampling out of a total of six
Sub-locations in Migwani will be done to get 4 Sub-locations. Within a Sub-location,
individual sampling units (Household with a child aged 12-59 months) will be selected using
a random walk method until the required sample size of 68 children is achieved per
Sub-location. Children who meet the inclusion criteria shall be randomly assigned to one of
the following treatment groups:
1. Maize porridge enriched with amaranth grain flour
2. Maize porridge fortified with a multiple micronutrient powder (MixMe™)
3. Plain maize porridge
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |